All In Biotech

Drug Trial Radar · NCT06974812

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

A Phase 1/2 Study of IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Apr 18, 2025

Primary completion

Jun 30, 2026

Study completion Jun 30, 2027

Sponsor

Sponsor type
Industry
First posted
May 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3014 in participants with unresectable locally advanced or metastatic solid tumors.

Conditions

  • Unresectable Locally Advanced or Metastatic Solid Tumors

Interventions

  • IBI3014Drug

    12 mg/kg D1 IV Q3W

  • IBI3014Drug

    6 mg/kg D1 IV Q3W

  • IBI3014Drug

    1 mg/kg D1 IV Q3W

  • IBI3014Drug

    15 mg/kg D1 IV Q3W

  • IBI3014Drug

    9 mg/kg D1 IV Q3W

  • IBI3014Drug

    3 mg/kg D1 IV Q3W

  • IBI3014Drug

    20 mg/kg D1 IV Q3W

  • IBI3014Drug

    18 mg/kg D1 IV Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Safety profile of patients in Phase 1 dose escalation part、Phase 1 dose expansion and Phase 2 dose optimizationTime frame: 2 years after LPI
  2. Dose limiting toxicity (DLT) of IBI3014 in Phase 1 dose escalationTime frame: 21 days after LPI
  3. ORR per RECIST v1.1 in Phase 1 dose expansion and Phase 2 dose optimizationTime frame: 2 years after LPI
  4. The Safety profile of patients in Phase 1 dose escalation part、Phase 1 dose expansion and Phase 2 dose optimizationTime frame: 2 years after LPI
  5. The Safety profile of patients in Phase 1 dose escalation part、Phase 1 dose expansion and Phase 2 dose optimizationTime frame: 2 years after LPI
  6. The Safety profile of patients in Phase 1 dose escalation part、Phase 1 dose expansion and Phase 2 dose optimizationTime frame: 2 years after LPI

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Fujian cancer hospital

    Fuzhou, Fujian, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.